An observational study in Choroidal Neovascularization, sponsored by Beijing Hospital. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Beijing Hospital · Observational
Choroidal neovascularization (CNV), also known as subretinal neovascularization, is a proliferative change from choroidal capillaries that has become one of the most important causes of blindness worldwide. CNV can occur in a variety of fundus diseases, including pathologic myopia, polypoidal choroidal vasculopathy. At present, intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs is the first-line effective treatment for CNV. Although a number of clinical studies have shown that the treatment of CNV with anti-VEGF drugs has achieved good visual and anatomical effects, there are still some patients whose CNV has not decreased significantly or even progressed continuously after treatment. Rapid advances in imaging technology have made it possible to explore the quantitative and qualitative characteristics of choroid and CNV, especially swept source optical coherence tomography angiography (SS-OCTA).
The objectives are to improve the OCTA typing of CNV and analyze the vascular morphological characteristics of each type; to identify the changes in vascular characteristics of CNV after anti-VEGF treatment in vitreous cavity; and to elucidate the predictive effects of neovascularization and choroidal vascular characteristics on visual acuity and anatomic effects of vitreous anti-VEGF drug treatment for CNV.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
This study's planned enrollment of 80 is close to the median of 79 across 42 observational studies indexed under Choroidal Neovascularization.
Browse Choroidal Neovascularization studies →Beijing Hospital is the lead sponsor of 51 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with choroidal neovascularization, who received standard 3-monthly anti-VEGF treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intravitreal injection of anti- vascular endothelial growth factor (VEGF) treatment
choroidal thickness
central choroidal thickness measured by SS-OCTA
Time frame: 3 months
Central retinal thickness
central retinal thickness changes measured by SS-OCTA
Time frame: 3 months
Best-corrected visual acuity
Best-corrected visual acuity changes from baseline to 3 months
Time frame: 3 months
choroidal vascularity index
the ratio of vascular area to the total choroidal area measured by SS-OCTA
Time frame: 3 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Choroidal Neovascularization →
Beijing Hospital